Technology Opportunities

Need: Nonalcoholic steatohepatitis (NASH) is a leading cause of morbidity and mortality with no effective therapy. However, there are numerous NASH drugs in clinical development, with a projected market during the 2020s of >$10B. The prevalence of NASH is ~7% worldwide and growing based on ...

Prof. Rifaat Safadi and his team are developing an inhaled formulation that combines two FDA-approved drugs, which recruit and activate certain types of immune cells in patients with Acute Respiratory Distress Syndrome (ARDS). The inhaled formulation will enable a safer use of the drugs ...